The unique ability of stem cells to perpetuate themselves through self-renewal, and to give rise to mature effector cell types in a sustained fashion has positioned stem cell biology at the forefront of regenerative medicine -- the goal of which is to develop strategies capable of harnessing the clinical potential of stem cells to treat both heritable and acquired degenerative conditions. Hematopoietic stem cells (HSCs) are the only cells within the bone marrow that possess the ability to both differentiate to all blood lineages, and to self-renew for life. These properties, along with the remarkable ability of HSCs to engraft conditioned recipients upon intravenous transplantation, have established the clinical paradigm for stem cell use in regenerative medicine. Despite the enormous clinical potential of HSCs, surprisingly little is known about the mechanisms that regulate their fundamental properties of self-renewal and multi-potency. Our lab has a profound interest in understanding the mechanisms enabling self-renewal and multi-potency in HSCs, which we study using cellular, molecular, genetic and epigenetic approaches.

Another focus of the lab is in understanding the extent to which the aging of hematopoietic stem and progenitor cells contributes to the pathophysiological conditions arising in the aged hematopoietic system, which include; declining immuno-competence, diminished stress response, anemia, and cancer. To address this we are evaluating hematopoietic stem and progenitor cells in the context of aging in order to determine the cellular and molecular mechanisms underlying the aging of the hematopoietic system. In particular we are exploring the contribution of epigenetic regulatory mechanisms to hematopoietic stem cell biology and aging. We are also studying the mechanisms through which stem cells maintain genomic integrity, and examining how age-dependent DNA damage accrual impacts stem cell functional capacity to contribute to hematopoietic pathophysiology.

Numerous studies have shown that it is possible to experimentally reprogram the cellular identity of one cell type to another. One approach to effect cellular reprogramming involves enforcing expression of defined transcriptional regulators important for specifying one cell type in a different cell type in order to convert its fate. This methodology is perhaps best exemplified by the generation of induced pluripotent stem (iPS) cells from a variety of differentiated cell types by the ectopic expression of a small number of defined factors. This approach is also proving to be a viable method to reprogram a variety of cell types to alternative fates. Our lab is pursuing several lines of investigation aimed at reprogramming the cellular identity of a number of cell types into clinically useful cell types through various approaches including the use of novel technologies.

Dr. Rossi received his Ph.D. from the University of Helsinki, Finland in 2003, and did his post-doctoral work in the lab of Dr. Irving Weissman at Stanford University. Dr. Rossi joined the IDI in 2007 as a Junior Investigator, and holds an appointment as Assistant professor in the Department of Pathology at Harvard Medical School. He is also a principal Faculty member of the Harvard Stem Cell Institute (HSCI). Dr. Rossi was awarded a K99/R00 Pathways to Independence award from the NIH and the National Institutes of Aging in 2006, and is also supported by grants from the Harvard Stem Cell Institute, the Helmsley Foundation, and GlaxoSmithKline.

Areas of Research

Learn more about research at the IDI by exploring our areas of research below: